AI English summary of an SEC filing — figures as filed
Bio-Techne TECHBio-Techne said net sales for the Q3 ended March 31, 2025 of fiscal 2025 increased 4% to $316.2 million, with organic revenue up 6%. The company cited foreign currency exchange and non-recurring prior year revenue from a business held-for-sale as each having an unfavorable impact of 1%.
Key points
AI summaryBio-Techne said net sales for the Q3 ended March 31, 2025 of fiscal 2025 increased 4% to $316.2 million, with organic revenue up 6%. The company cited foreign currency exchange and non-recurring prior year revenue from a business held-for-sale as each having an unfavorable impact of 1%.
The company said GAAP operating income for the Q3 decreased 42% to $38.7 million, compared to $67.0 million in the prior year quarter, and GAAP operating margin was 12.2%, compared to 22.1% in the prior year quarter. Bio-Techne said current quarter GAAP operating margin was unfavorably impacted by a non-recurring arbitration award.
Bio-Techne said adjusted operating income for the Q3 increased 11% to $110.3 million, compared to $99.6 million in the prior year quarter, adjusted operating margin was 34.9%, compared to 33.0% in the prior year quarter, and adjusted diluted EPS was $0.56, compared to $0.48 in the prior year quarter. The company said adjusted operating margin was impacted by favorable volume leverage and profitability initiatives.
Bio-Techne disclosed that operating cash flow for the 9 months ended March 31, 2025 of fiscal 2025 was $189,355 thousand, and that it used $175,674 thousand for common stock repurchases and $38,004 thousand for cash dividends during the same period.
Summary
AI-writtenAnalysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.
Fiscal 2025 Q3 revenue and organic revenue growth
Bio-Techne said net sales for the Q3 ended March 31, 2025 of fiscal 2025 increased 4% to $316.2 million, with organic revenue up 6%. The company cited foreign currency exchange and non-recurring prior year revenue from a business held-for-sale as each having an unfavorable impact of 1%.
Source · Based on the filing body and exhibits
GAAP operating income decline and arbitration award impact
The company said GAAP operating income for the Q3 decreased 42% to $38.7 million, compared to $67.0 million in the prior year quarter, and GAAP operating margin was 12.2%, compared to 22.1% in the prior year quarter. Bio-Techne said current quarter GAAP operating margin was unfavorably impacted by a non-recurring arbitration award.
Source · Based on the filing body and exhibits
Adjusted operating income and adjusted EPS
Bio-Techne said adjusted operating income for the Q3 increased 11% to $110.3 million, compared to $99.6 million in the prior year quarter, adjusted operating margin was 34.9%, compared to 33.0% in the prior year quarter, and adjusted diluted EPS was $0.56, compared to $0.48 in the prior year quarter. The company said adjusted operating margin was impacted by favorable volume leverage and profitability initiatives.
Source · Based on the filing body and exhibits
Fiscal 2025 9-month cash flow: share repurchases and operating cash
Bio-Techne disclosed that operating cash flow for the 9 months ended March 31, 2025 of fiscal 2025 was $189,355 thousand, and that it used $175,674 thousand for common stock repurchases and $38,004 thousand for cash dividends during the same period.
Source · Based on the filing body and exhibits
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…